Rona Yaeger
New York oncologist who was lead author of the KRYSTAL-1 colorectal report, which showed adagrasib with cetuximab shrinks KRAS G12C-mutant colorectal cancer and led to the combination's approval.
Overview
Rona Yaeger is a gastrointestinal medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center. She was first author of the 2023 New England Journal of Medicine report of the KRYSTAL-1 cohorts in which adagrasib alone and with cetuximab produced responses in heavily pretreated KRAS G12C-mutant metastatic colorectal cancer, the basis of the combination's accelerated approval. Her laboratory studies mechanisms of resistance to RAS and BRAF inhibitors.
Similar pages
not linked directly; found by shared links- PersonJohn H. Strickler
Shares Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonAndrea Sartore-Bianchi
Shares Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonSalvatore Siena
Shares Colorectal cancer and the tags colorectal, targeted-therapy, trialist.
- PersonGerald W. Prager
Shares KRAS G12C-mutant colorectal cancer, Colorectal cancer and the tags colorectal, trialist.
- PersonScott Kopetz
Shares BRAF V600E-mutant colorectal cancer, Colorectal cancer and the tags colorectal, targeted-therapy.
- PersonPaul B. Chapman
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
- PersonGregory J. Riely
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.
- PersonPaul K. Paik
Shares Memorial Sloan Kettering Cancer Center and the tags targeted-therapy, trialist.